Cargando…

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales:	Johnson, Nathalie, Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia, Timmerman, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431363/ http://dx.doi.org/10.1097/01.HS9.0000971156.02746.02

Ejemplares similares

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
por: Gregory, G., et al.
Publicado: (2022)

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
por: Timmerman, John, et al.
Publicado: (2023)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
por: Herrera, A. F., et al.
Publicado: (2022)

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Armand, Philippe, et al.
Publicado: (2023)

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
por: Garralda, E., et al.
Publicado: (2022)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

Antiretroviral activity of aminothiols, WR2721 and WR1065
por: Poirier, Miriam C, et al.
Publicado: (2006)

Synthesis and cytotoxicity of a biotinylated CC-1065 analogue
por: Wang, Yuqiang, et al.
Publicado: (2002)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

1065. Evaluation of a Staphylococcus aureus Bacteremia Treatment Checklist
por: Soukup, Hailey, et al.
Publicado: (2018)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Conformational changes in chromatin structure induced by the radioprotective aminothiol, WR 1065.
por: Vaughan, A. T., et al.
Publicado: (1989)

1065. Keeping Score: Utilizing a Prioritization Tool to Create Multidisciplinary Antimicrobial Stewardship Documentation
por: Mediwala, Krutika N, et al.
Publicado: (2019)

Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study
por: Esser, Peter, et al.
Publicado: (2023)

Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug
por: Wang, Yuqiang, et al.
Publicado: (2001)

1065. Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits
por: Petraitis, Vidmantas, et al.
Publicado: (2021)

P1065: CONGENITAL ERYTHROCYTOSIS DUE TO HETEROZYGOUS VARIANTS IN THE BISPHOSPHOGLYCERATE MUTASE GENE
por: van Dijk, M. J., et al.
Publicado: (2022)

Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats
por: Kheradmand, Afshin, et al.
Publicado: (2016)

Analysis and Management of Complications in a Cohort of 1,065 Minimally Invasive Cochlear Implantations
por: Jiang, Yi, et al.
Publicado: (2017)

1065 Worldwide COVID-19-related knowledge, impact, and worry in pregnant people and their partners
por: Dye, Timothy D., et al.
Publicado: (2021)

Phosphorylation at Y1065 in Vinculin Mediates Actin Bundling, Cell Spreading, and Mechanical Responses to Force
por: Tolbert, Caitlin E., et al.
Publicado: (2014)

1065. Hepatitis C Virus Care Cascade Assessment–One Step Closer to Micro-Elimination
por: Chowdhury, Jehan F, et al.
Publicado: (2020)

Study of Surface Modifications of Textile Card Clothing (AISI 1065 Alloy) by Laser Shock Peening
por: Dhakshinamoorthy, Praveena, et al.
Publicado: (2023)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

CLL and COVID-19: light at the end of the tunnel?
por: Scarfò, Lydia, et al.
Publicado: (2022)

Determination of the Biological Activity and Structure Activity Relationships of Drugs Based on the Highly Cytotoxic Duocarmycins and CC-1065
por: Tietze, Lutz F., et al.
Publicado: (2009)

Correction to Phosphorylation at Y1065 in Vinculin Mediates Actin Bundling, Cell Spreading, and Mechanical Responses to Force
por: Tolbert, Caitlin E., et al.
Publicado: (2014)

Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients
por: Szász, A. Marcell, et al.
Publicado: (2016)

SG-APSIC1065: The effectiveness of an ultraviolet-C device for terminal room disinfection in an intensive care unit
por: Shi, Zhi-Yuan, et al.
Publicado: (2023)

Vital signs and their cross-correlation in sepsis and NEC: A study of 1065 very low birth weight infants in two NICUs
por: Fairchild, Karen D., et al.
Publicado: (2016)

Run 1065 MD - 15th October 1979, Vacuum Tests in Ring 2 (46.8 A)
por: Calder, R, et al.
Publicado: (1979)

Run 1065 MD - 15th October 1979, Vacuum Tests in Ring 1 (50.8 A)
por: Calder, R, et al.
Publicado: (1979)

Draft genome sequence and probiotic functional property analysis of Lactobacillus gasseri LM1065 for food industry applications
por: Bae, Won-Young, et al.
Publicado: (2023)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

Rituximab-Related Pulmonary Toxicity
por: Herishanu, Yair, et al.
Publicado: (2010)

The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
por: Bronstein, Yotam, et al.
Publicado: (2022)

Total cross section of the reaction K-p→K̅0n from 515 to 1065 MeV/c
por: Alston-Garnjost, M, et al.
Publicado: (1978)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6b33vs664eh8km27h0c8k74gj3